Futura Medical plc (“Futura”) develops
innovative products for the consumer
healthcare market.
The Company´s strategy is to develop innovative products and
out–license their manufacture and distribution to major pharmaceutical
and healthcare groups.
Futura is developing a portfolio of products in sexual healthcare and pain
relief management and is evaluating further therapeutic opportunities as
potential additions to its pipeline.
Futura´s shares trade on the AIM market of the London Stock Exchange
and the Company is based at The Surrey Research Park, Guildford, Surrey.
Our business strategy is centred on selecting and
developing products based on five key criteria:
• Return on Investment: we focus on consumer
healthcare products that offer the potential for a
significant return on the costs of development.
• Product Profile: we focus on topically applied
medicines, either stand–alone or in combination with a
medical device. We only incorporate existing chemical
entities into our products which gives our development
activities a lower risk profile.
• Over The Counter (“OTC”): our aim is to produce
safe and effective OTC products made available to
consumers on a general retail basis or through chemists
without the need for a doctor´s prescription.
• Strong Intellectual Property: the products are
underpinned by our developing and retaining valuable
intellectual property including know–how, patents and
trademarks to protect their commercial position.
• Licensing: we aim to out–license our products during
their development to established pharmaceutical
and healthcare groups which offer the best potential
commercial opportunities.
